Special Programme of Research, Development and Research Training in Human Reproduction


Book Description

This highly regarded organization is one of the few engaged in contraceptive research and development that focuses on the needs of the developing world. The Special Programme of Research, Development and Research Training in Human Reproduction (HRP) merits the Bank's continued and expanded support.




Current Catalog


Book Description

First multi-year cumulation covers six years: 1965-70.




Consolidated Guideline on Sexual and Reproductive Health and Rights of Women Living with HIV


Book Description

he starting point for this guideline is the point at which a woman has learnt that she is living with HIV and it therefore covers key issues for providing comprehensive sexual and reproductive health and rights-related services and support for women living with HIV. As women living with HIV face unique challenges and human rights violations related to their sexuality and reproduction within their families and communities as well as from the health-care institutions where they seek care particular emphasis is placed on the creation of an enabling environment to support more effective health interventions and better health outcomes. This guideline is meant to help countries to more effectively and efficiently plan develop and monitor programmes and services that promote gender equality and human rights and hence are more acceptable and appropriate for women living with HIV taking into account the national and local epidemiological context. It discusses implementation issues that health interventions and service delivery must address to achieve gender equality and support human rights.













Index of NLM Serial Titles


Book Description

A keyword listing of serial titles currently received by the National Library of Medicine.




70 Years of Population Policy


Book Description

In response to the close link between economic and population issues recognized by the United Nations in 1957, the World Health Organization (WHO) was prompted to address the concerns of developing nations dealing with slow economic growth and high population growth by 1964. Establishing the Human Reproduction Unit in 1965, WHO outlined its strategy in 1965, acknowledging the repercussions of population changes on health conditions. A pivotal development occurred in 1970 when global organizations convened to discuss a research program on human reproduction, leading to the creation of the Expanded Programme of Research, Development, and Research Training in Human Reproduction (HRP) in 1971. The HRP, with its scientifically authoritative and neutral methods, significantly contributed to the development of contraception methods, which are still in use today. Additionally, the program played a role in disseminating these methods through a discourse rooted in human rights principles. This historical narrative highlights WHO's enduring commitment to addressing global health challenges related to population and reproductive health.







Future Aspects in Contraception


Book Description

Atrophy of gonadotrophin producing cells Exogenously LH synthesis administered androgens and release or anabolic steroids are decreased Prostate Testes Normal function. Testosterone synthesis in The deficit of endogenously Leydig cells is decreased. The synthesized testosterone is exogenously administered compensated for by the steroid is not able to exogenously administered compensate for the deficit of steroid endogenously synthesized testosterone Figure 2 Intratesticular and serum testosterone concentrations after treatment with andro gens or anabolic steroids in order to substitute for the peripheral androgen deficiency and to achieve azoospermia. Because this steroid is alkylated in position 17, toxic effects on liver function can not be excluded. Danazol offers no advantages as compared with other anabolic steroids; rather, disadvantages. Numerous experiments of this type have been performed during the last 40 or 50 years. The outcome in each case was more or less identical: with a certain dose of an androgen or anabolic steroid it is possible to inhibit spermatogenesis without interfering with other androgen-dependent func tions, including libido (potentia coeundi) and accessory sexual glands. On the basis of this pharmacological-endocrinological background, androgens and anabolic steroids can be used for male fertility control, and several clinical trials have been performed during the last 10-15 years. Some of 1 these studies 2-23 are mentioned in Table 2.